Study to Investigate the Immune Response to Influenza Vaccine in Patients With Multiple Sclerosis on Teriflunomide

Exclusion Criteria

• •Concomitant infectious pathology at the time of vaccination;
• •MS relapse within 1 month before vaccination;
• •Systemic corticosteroids within 1 month before the vaccination;
• •Any contraindication to influenza vaccine;
• •Any vaccination within the last 6 months;
• •Prior use of any investigational drug or participation to a clinical trial within 1 year (only for patients under interferon-β-1);
• •Prior or concomitant use (for a minimum of 1 year before study entry) of cladribine, mitoxantrone, or other immunosuppressant agents such as azathioprine, cyclophosphamide, cyclosporin, methotrexate, mycophenolate, natalizumab (Tysabri®), leflunomide or fingolimod or other immunomodulator/immunosuppressant in development;
• •Prior or concomitant use of glatiramer acetate within 1 year before study entry;
• •Prior or concomitant use of intravenous immunoglobulins within 3 months before study entry;
• •Pregnant or breast feeding women;
• •Woman of childbearing potential without adequate contraception.
• •The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.